An unmet need: tailoring extended adjuvant endocrine therapy.

about

Status of adjuvant endocrine therapy for breast cancer.

P2860

Q33739138-F84BCAD8-D724-4F37-9364-CA8A82FF5F1A

P2860

An unmet need: tailoring extended adjuvant endocrine therapy.

Item

http://www.wikidata.org/entity/Q42813847

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

An unmet need: tailoring extended adjuvant endocrine therapy.

@en

An unmet need: tailoring extended adjuvant endocrine therapy.

@nl

type

Item

label

An unmet need: tailoring extended adjuvant endocrine therapy.

@en

An unmet need: tailoring extended adjuvant endocrine therapy.

@nl

prefLabel

An unmet need: tailoring extended adjuvant endocrine therapy.

@en

An unmet need: tailoring extended adjuvant endocrine therapy.

@nl

P1476

An unmet need: tailoring extended adjuvant endocrine therapy.

@en

P2093

G Bianchini

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Supervised risk predictor of breast cancer based on intrinsic subtypes

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.

P2888

bjc.2013.707

P304

2951-2953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1038/BJC.2013.707

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Luca Gianni

P577

2013-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258766698

http://www.w3.org/2001/XMLSchema#string

P698

24253504

http://www.w3.org/2001/XMLSchema#string

P932

3859956

http://www.w3.org/2001/XMLSchema#string

An unmet need: tailoring extended adjuvant endocrine therapy.

about

P2860

P2860

An unmet need: tailoring extended adjuvant endocrine therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932